CombinatoRx's stock plummets after Phase II failure
This article was originally published in Scrip
Executive Summary
The failure of CombinatoRx's (CRXX) lead product, Synavive (CRx-102), to reach its Phase II primary endpoint sent its stock into freefall on October 6th, closing down by 76.67% to $0.70 on Nasdaq.